Literature DB >> 6801203

Transport of GABA at the blood-CSF interface.

W Löscher, H H Frey.   

Abstract

The entry of GABA into cerebrospinal fluid (CSF) was studied in dogs anesthetized with pentobarbital and relaxed with suxamethonium. GABA was administered intravenously as a priming dose and subsequent maintenance infusion to compensate for the rapid elimination of the amino acid. Steady state concentrations of GABA in CSF were reached between 10 and 60 min after injection, the rate of entry tending to decrease with increasing plasma levels. During steady state conditions CSF concentrations showed great interindividual differences and varied between 0.03 and 5.1% of those in plasma. Probenecid and sodium valproate considerably enhanced the CSF/plasma concentration ratio of GABA. When GABA was directly injected into the liquor space, probenecid slowed down the elimination of GABA from CSF. The results suggest a transport of GABA into and out of CSF, the outward transport being inhibited by probenecid and sodium valproate.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6801203     DOI: 10.1111/j.1471-4159.1982.tb05350.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

Review 1.  The impact of efflux transporters in the brain on the development of drugs for CNS disorders.

Authors:  Eve M Taylor
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Elevated plasma gamma-aminobutyric acid (GABA) levels in individuals with either Prader-Willi syndrome or Angelman syndrome.

Authors:  M H Ebert; D E Schmidt; T Thompson; M G Butler
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1997       Impact factor: 2.198

3.  Peripartum neuroactive steroid and γ-aminobutyric acid profiles in women at-risk for postpartum depression.

Authors:  Kristina M Deligiannidis; Aimee R Kroll-Desrosiers; Shunyan Mo; Hien P Nguyen; Abby Svenson; Nina Jaitly; Janet E Hall; Bruce A Barton; Anthony J Rothschild; Scott A Shaffer
Journal:  Psychoneuroendocrinology       Date:  2016-05-09       Impact factor: 4.905

4.  The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression.

Authors:  Esra Küçükibrahimoğlu; Melek Z Saygin; Mecit Calişkan; Okan K Kaplan; Cüneyt Unsal; M Zafer Gören
Journal:  Eur J Clin Pharmacol       Date:  2009-04-17       Impact factor: 2.953

5.  Synergistic effect of phosphatidylserine with gamma-aminobutyric acid in antagonizing the isoniazid-induced convulsions in mice.

Authors:  G Toffano; S Mazzari; A Zanotti; A Bruni
Journal:  Neurochem Res       Date:  1984-08       Impact factor: 3.996

6.  Decreased Hepatocyte Growth Factor (HGF) and Gamma Aminobutyric Acid (GABA) in Individuals with Obsessive-Compulsive Disorder (OCD).

Authors:  Anthony J Russo; Stefanie C Pietsch
Journal:  Biomark Insights       Date:  2013-08-18

7.  Homotaurine, a safe blood-brain barrier permeable GABAA-R-specific agonist, ameliorates disease in mouse models of multiple sclerosis.

Authors:  Jide Tian; Hoa Dang; Martin Wallner; Richard Olsen; Daniel L Kaufman
Journal:  Sci Rep       Date:  2018-11-08       Impact factor: 4.379

8.  Homotaurine Treatment Enhances CD4+ and CD8+ Regulatory T Cell Responses and Synergizes with Low-Dose Anti-CD3 to Enhance Diabetes Remission in Type 1 Diabetic Mice.

Authors:  Jide Tian; Hoa Dang; Karen Anne O'Laco; Min Song; Bryan-Clement Tiu; Spencer Gilles; Christina Zakarian; Daniel L Kaufman
Journal:  Immunohorizons       Date:  2019-10-21

9.  Permeation thresholds for hydrophilic small biomolecules across microvascular and epithelial barriers are predictable on basis of conserved biophysical properties.

Authors:  Hemant Sarin
Journal:  In Silico Pharmacol       Date:  2015-05-03

Review 10.  Neurotransmitters as food supplements: the effects of GABA on brain and behavior.

Authors:  Evert Boonstra; Roy de Kleijn; Lorenza S Colzato; Anneke Alkemade; Birte U Forstmann; Sander Nieuwenhuis
Journal:  Front Psychol       Date:  2015-10-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.